Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. - Wikidata - wikimedia - TriplyDB

Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

http://www.wikidata.org/entity/Q34529820

about

Acquired pure red cell aplasia: updated review of treatment Analytics of nonpeptidic erythropoietin mimetic agents in sports drug testing employing high-resolution/high-accuracy liquid chromatography-mass spectrometry.Lipid, blood pressure and kidney update 2013.The role of anemia management in improving outcomes for African-Americans with chronic kidney disease Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.A screen for peptide agonists of the G-CSF receptor Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes.An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients.Erythropoietin after a century of research: younger than ever.Effects of Peginesatide Injection on QTc Interval in Healthy Adults.Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients.Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis.Erythropoietic agents and the elderly.CERA: third-generation erythropoiesis-stimulating agent.Internal medicine, renal anaemia, and erythropoiesis-stimulating agents (ESAS).Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents.Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide.Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis.Erythropoietic stimulating agents.Erythropoietin receptor response circuits Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events.Hematide™ for the treatment of chronic kidney disease-related anemia.Recent developments in doping testing for erythropoietin.Detection of erythropoiesis-stimulating agents in human anti-doping control: past, present and future.Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.Peginesatide for the treatment of renal disease-induced anemia.Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.Treatment of anemia in chronic kidney disease: known, unknown, and both.EPOR-Based Purification and Analysis of Erythropoietin Mimetic Peptides from Human Urine by Cys-Specific Cleavage and LC/MS/MS.Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats Anaemia: The safety and efficacy of peginesatide in patients with CKD."Bio"-macromolecules: polymer-protein conjugates as emerging scaffolds for therapeutics.A subchronic murine intravenous pharmacokinetic and toxicity study of Hematide™, a PEGylated peptidic erythropoiesis-stimulating agent.Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers.Emerging drugs: mechanism of action, mass spectrometry and doping control analysis.Genotoxic assessment and toxicity evaluation of peginesatide in CByB6F1 hybrid mice.Erythropoiesis equivalence, pharmacokinetics and immune response following repeat hematide administration in cynomolgus monkeys.

P2860

Q24652253-8F5F7F9C-7EF4-49B2-92DF-C61A06DE933A Q30390786-9A87DDF4-71CF-4F09-B490-CC5CEFF3BE01 Q33574532-27CCAC40-0814-4D7C-AC42-0636E1A24AAE Q33646679-C349CC86-1292-45FD-A364-12663D0F8F51 Q33655344-111FD8D2-D0C7-4D4C-9EE7-2CF9B19677BE Q33933699-0F709019-5C03-42E2-80E6-FAFF24E2EDDC Q33944531-42B6827A-5064-4FFA-943D-7CF686141F87 Q34398392-EB3AE38D-6553-4011-B6C8-90A07AAF4F09 Q34606348-A08E6CA8-F38F-4796-A9FA-F9F61C869658 Q35810325-6E4A3C5D-D62B-44F0-A762-43C9362C52C8 Q35985899-5F82AFB0-0D75-4270-A264-F0DFF948766F Q36039649-11AA16F8-A077-4CAC-8FDB-0F011B6F159E Q37098040-244E3912-3DD7-4794-AF42-85D28A964557 Q37111869-86137953-FCA5-435B-92FB-BF56E214E2A2 Q37113720-D2C53B35-D666-4C64-80E2-20F8C578EF01 Q37154338-4603E3AC-205A-4CB1-BA97-FDBC7392B5E3 Q37157237-0C1B68C3-FF56-42ED-A8DF-E3FB7E6AA3E6 Q37359343-A6B3CC0C-1758-4E36-B81B-FB950FAEB190 Q37693160-00F5C4FB-8214-4D98-A115-23097B655CD2 Q37696206-6DFD7B14-9C78-4AD9-9E7A-9F0EBEF45BB1 Q37700912-106FEA3B-DD4E-46C4-A42E-8E319A97A2DF Q37810076-53BBCA19-0BB8-4B10-9BDA-9A3BF44D9132 Q37884431-08181E5A-C5C7-4E45-A420-F167C4C15373 Q38029405-0B10156A-ED15-4EC2-AB2C-05EDAE34C820 Q38075798-51A05EF5-FA37-4745-BC07-49F9C7304FCF Q38090725-BDFB0CC4-C54C-4D09-BD6E-EF1070D18C82 Q38126361-8A4616B5-E39B-4B35-8359-8E3408758296 Q40540575-9E977AAE-4C12-4CF2-A8DC-A9C7C17CE0C9 Q40785295-6748F023-3ED8-45C6-A77A-F4940F9D33A8 Q41892226-C8EDDFAB-F5DF-437D-9377-D7876C27CB95 Q42257325-B75F11B3-A019-4BA4-B3C6-F211995D5B51 Q44067854-8E69FB29-2CD5-4BFD-BCEA-FD6BF84C4CD2 Q46335892-E1FCDEBB-F8C9-45DD-815F-EC354A7F0456 Q46807825-B6A23DBC-A4A9-4F24-A845-9D7F009012B1 Q46891656-F27D5530-6408-45D0-A115-08B023C76F91 Q47992683-6591155E-8F25-4CEA-BCE8-FD815F8545B4 Q50041581-B773CDD3-CE98-4F82-8AE1-5791F531A55E Q50581034-5D90B8F1-BE07-4A7A-8061-E70FF2905007

P2860

Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

http://www.wikidata.org/entity/Q34529820

description

2006 nî lūn-bûn

@nan

2006 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Evaluation of the safety and p ...... n study in healthy volunteers.

@ast

Evaluation of the safety and p ...... n study in healthy volunteers.

@en

Evaluation of the safety and p ...... n study in healthy volunteers.

@nl

type

label

Evaluation of the safety and p ...... n study in healthy volunteers.

@ast

Evaluation of the safety and p ...... n study in healthy volunteers.

@en

Evaluation of the safety and p ...... n study in healthy volunteers.

@nl

prefLabel

Evaluation of the safety and p ...... n study in healthy volunteers.

@ast

Evaluation of the safety and p ...... n study in healthy volunteers.

@en

Evaluation of the safety and p ...... n study in healthy volunteers.

@nl

P1433

Q34529820-953A16F6-BABC-47CE-BCAA-47987EE8C506

P1476

Q34529820-2253139A-5017-4C64-A379-55F9B6DF2771

P2093

Q34529820-0FEC70E0-886D-45FF-A2D8-F8A48C76DAAD

Q34529820-2674D573-F1BD-4A9B-8756-6B103937CBCF

Q34529820-A01952EB-6B06-41CB-BB6D-FA616C3AE696

Q34529820-A0FFB48D-0604-414F-B129-8CD2AFFDE37F

Q34529820-AC4E0082-A115-43C7-B7EB-E8E68A79105E

Q34529820-AD731FDB-92FB-40B7-A2AC-822E3367F776

Q34529820-B727455E-A129-4007-842D-0493D197B31D

Q34529820-BEAAD5B0-941F-44B1-8060-7687BDBD9FCA

Q34529820-D72CF718-4552-4B6B-9BF1-C66D19091403

P304

Q34529820-3F7DA070-1FEB-444F-9E60-FAAB45621DD1

P31

Q34529820-C2C650BE-8D04-4E5D-B08C-178FB28086B0

P356

Q34529820-91FDBF1C-07E1-48E3-A956-27C3D9EC2828

P407

Q34529820-152FC459-5131-4855-A2D7-69D5A427B66A

P433

Q34529820-28CB3290-BDB9-4679-8FF9-1DD9D63F6F78

P478

Q34529820-CB67BB08-2E3C-4147-9D6E-EA55458DAE1F

P50

Q34529820-D37CA043-040E-4B4E-851D-C59D9319746D

P577

Q34529820-0766E4B8-EC2A-48F6-A50A-BC1B5D971B00

P5875

Q34529820-9C197FF2-AA5B-42C9-8295-4C63CA1F825C

P698

Q34529820-CA59BF1A-4D72-4BEB-BFF9-56FA8F56D134

P921

Q34529820-7A29E2C6-E785-40A8-8EE6-7993FC3BD9E2

P356

BLOOD-2006-04-015818

P1433

P1476

Evaluation of the safety and p ...... on study in healthy volunteers

@en

P2093

Anne-Marie Duliege

http://www.w3.org/2001/XMLSchema#string

Dawie Wessels

http://www.w3.org/2001/XMLSchema#string

Douglas M Okamoto

http://www.w3.org/2001/XMLSchema#string

John Lambert

http://www.w3.org/2001/XMLSchema#string

Julie S Iwashita

http://www.w3.org/2001/XMLSchema#string

Kerstin K Leuther

http://www.w3.org/2001/XMLSchema#string

Peter J Schatz

http://www.w3.org/2001/XMLSchema#string

Richard B Stead

http://www.w3.org/2001/XMLSchema#string

Robert Naso

http://www.w3.org/2001/XMLSchema#string

P304

1830-1834

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2006-04-015818

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Kathryn Woodburn

P577

2006-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7061547

http://www.w3.org/2001/XMLSchema#string

P698

16720830

http://www.w3.org/2001/XMLSchema#string

P921